Literature DB >> 27957043

Silent Cerebral Events after Atrial Fibrillation Ablation - Overview and Current Data.

Thomas Deneke1, Karin Nentwich2, Joachim Krug2, Patrick Müller1, Peter Hubert Grewe3, Andreas Mügge3, Anja Schade2.   

Abstract

Silent cerebral lesions (SCL) have been identified on brain magnetic resonance imaging (MRI) in apparently asymptomatic patients after cardiovascular procedures. After atrial fibrillation (AF) ablation incidences range from 1 to over 40% depending upon different factors. MRI definition should include diffusion weighted imaging (DWI) to detect hyperintensities (bright spots) due to acute brain ischemia correlated with a hypointensity in the apparent diffusion coefficient mapping (ADC-map) to rule out artifacts. The genesis of SCL appears to be multifactorial and appears to be a result of embolic events either from gaseous or solid particles. The MRI pattern appears to be comparable not hinting towards a specific mechanism. One may distinguish two different MRI definition: one, more sensitive, for silent ischemic events (SCE) not proven to be related to cell death (DWI positive but FLAIR negative); and one for SCL that are due to edema caused by cell death which will lead to glial cell scar formation (DWI positive and FLAIR positive). For ease of data interpretation, future studies should ensure both definitions, and that DWI and FLAIR data is acquired using identical slice thickness and orientation. Risk factors associated with increased SCL-incidences involve patient-specific, technology-associated and procedural determinants. When using a high-sensitive MRI definition differences in SCE-rates in between technologies appear to be less prominent. Further studies on the effects of different periprocedural anticoagulation regimen, different steps of the ablation procedure and new technologies are needed. For now, SCL incidence may determine the thrombogenic potential of an ablation technology and further studies to reduce or avoid SCL generation are desirable. It appears reasonable, that any SCE should be avoided.

Entities:  

Year:  2014        PMID: 27957043      PMCID: PMC4956131          DOI: 10.4022/jafib.996

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  21 in total

1.  Late resolution of diffusion-weighted MRI changes in a patient with prolonged reversible ischemic neurological deficit after thrombolytic therapy.

Authors:  K Krueger; H Kugel; M Grond; A Thiel; D Maintz; K Lackner
Journal:  Stroke       Date:  2000-11       Impact factor: 7.914

2.  Cerebral embolism following transcatheter aortic valve implantation: comparison of transfemoral and transapical approaches.

Authors:  Josep Rodés-Cabau; Eric Dumont; Robert H Boone; Eric Larose; Rodrigo Bagur; Ronen Gurvitch; Fernand Bédard; Daniel Doyle; Robert De Larochellière; Cleonie Jayasuria; Jacques Villeneuve; Alier Marrero; Mélanie Côté; Philippe Pibarot; John G Webb
Journal:  J Am Coll Cardiol       Date:  2011-01-04       Impact factor: 24.094

3.  Intracranial emboli associated with catheter ablation of atrial fibrillation: has the silence finally been broken?

Authors:  Jonathan S Steinberg; Suneet Mittal
Journal:  J Am Coll Cardiol       Date:  2011-08-09       Impact factor: 24.094

4.  Postablation asymptomatic cerebral lesions: long-term follow-up using magnetic resonance imaging.

Authors:  Thomas Deneke; Dong-In Shin; Osman Balta; Kathrin Bünz; Frank Fassbender; Andreas Mügge; Helge Anders; Marc Horlitz; Markus Päsler; Sinthu Karthikapallil; Thomas Arentz; Dieter Beyer; Martin Bansmann
Journal:  Heart Rhythm       Date:  2011-07-02       Impact factor: 6.343

5.  Silent cerebral embolism and new technologies for catheter ablation of atrial fibrillation: time to take a deep breath.

Authors:  Antonio Sorgente; Antonia Ceccarelli; Riccardo Cappato
Journal:  J Cardiovasc Electrophysiol       Date:  2012-11-06

6.  Incidence and long-term follow-up of silent cerebral lesions after pulmonary vein isolation using a remote robotic navigation system as compared with manual ablation.

Authors:  Andreas Rillig; Udo Meyerfeldt; Roland Richard Tilz; Jochen Talazko; Anita Arya; Vlada Zvereva; Ralf Birkemeyer; Tomislav Miljak; Bajram Hajredini; Peter Wohlmuth; Ulrich Fink; Werner Jung
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-01-13

7.  Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation.

Authors:  Jan Wilko Schrickel; Lars Lickfett; Thorsten Lewalter; Erica Mittman-Braun; Stephanie Selbach; Katharina Strach; Claas P Nähle; Jörg Otto Schwab; Markus Linhart; Rene Andrié; Georg Nickenig; Torsten Sommer
Journal:  Europace       Date:  2010-01       Impact factor: 5.214

8.  3 Tesla MRI-detected brain lesions after pulmonary vein isolation for atrial fibrillation: results of the MACPAF study.

Authors:  Karl Georg Haeusler; Lydia Koch; Juliane Herm; Ute A Kopp; Peter U Heuschmann; Matthias Endres; Heinz-Peter Schultheiss; Alexander Schirdewan; Jochen B Fiebach
Journal:  J Cardiovasc Electrophysiol       Date:  2012-08-22

9.  A prospective randomized single-center study on the risk of asymptomatic cerebral lesions comparing irrigated radiofrequency current ablation with the cryoballoon and the laser balloon.

Authors:  Boris Schmidt; Melanie Gunawardene; Detlef Krieg; Stefano Bordignon; Alexander Fürnkranz; Mehmet Kulikoglu; Wilfried Herrmann; K R Julian Chun
Journal:  J Cardiovasc Electrophysiol       Date:  2013-04-18

10.  Microembolism and catheter ablation I: a comparison of irrigated radiofrequency and multielectrode-phased radiofrequency catheter ablation of pulmonary vein ostia.

Authors:  David E Haines; Mark T Stewart; Sarah Dahlberg; Noah D Barka; Cathy Condie; Gary R Fiedler; Nicole A Kirchhof; Franck Halimi; Thomas Deneke
Journal:  Circ Arrhythm Electrophysiol       Date:  2013-02-07
View more
  6 in total

1.  Meta-analysis of the safety and efficacy of using minimally interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation.

Authors:  Yin-Jun Mao; Hang Wang; Pin-Fang Huang
Journal:  J Interv Card Electrophysiol       Date:  2020-05-02       Impact factor: 1.900

Review 2.  Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials.

Authors:  Rhanderson Cardoso; Stephan Willems; Edward P Gerstenfeld; Atul Verma; Richard Schilling; Stefan H Hohnloser; Ken Okumura; Matias Nordaby; Marc A Brouwer; Hugh Calkins
Journal:  Clin Cardiol       Date:  2018-12-07       Impact factor: 2.882

Review 3.  [Pulsed field ablation : The ablation technique of the future?]

Authors:  Nico Reinsch; Anna Füting; Dennis Höwel; Kars Neven
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2022-01-07

4.  Cerebral thromboembolic risk in atrial fibrillation ablation: a direct comparison of vitamin K antagonists versus non-vitamin K-dependent oral anticoagulants.

Authors:  Adrian Petzl; Michael Derndorfer; Georgios Kollias; Kgomotso Moroka; Josef Aichinger; Helmut Pürerfellner; Martin Martinek
Journal:  J Interv Card Electrophysiol       Date:  2020-03-06       Impact factor: 1.900

5.  Safety, effectiveness, and quality of life following pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter in paroxysmal atrial fibrillation: 1-year outcomes from SHINE.

Authors:  Richard Schilling; Gurpreet Singh Dhillon; Claudio Tondo; Stefania Riva; Massimo Grimaldi; Federico Quadrini; Petr Neuzil; Gian-Battista Chierchia; Carlo de Asmundis; Ahmed Abdelaal; Liesbeth Vanderlinden; Tiffany Tan; Wern Yew Ding; Dhiraj Gupta; Vivek Y Reddy
Journal:  Europace       Date:  2021-06-07       Impact factor: 5.214

6.  Atrial Fibrillation Ablation Using Robotic Magnetic Navigation Reduces the Incidence of Silent Cerebral Embolism.

Authors:  Jie Zheng; Meng Wang; Qun-Feng Tang; Feng Xue; Ku-Lin Li; Shi-Peng Dang; Xiao-Yu Liu; Xiao-Xi Zhao; Chang-Ying Zhang; Zhi-Ming Yu; Bing Han; Ting-Bo Jiang; Yan Yao; Ru-Xing Wang
Journal:  Front Cardiovasc Med       Date:  2021-12-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.